<DOC>
	<DOC>NCT00409019</DOC>
	<brief_summary>The purpose of this study is to find out if taking a combination of telbivudine and adefovir or tenofovir and telbivudine can lower the amount of Hepatitis B virus in patients that have been taking adefovir alone for at least 5 months and have had less than optimal responses. The safety of taking telbivudine and adefovir together or tenofovir and telbivudine together will also be studied.</brief_summary>
	<brief_title>Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Documented compensated chronic hepatitis B defined by clinical history compatible with chronic hepatitis B Patient is currently receiving Hepsera (adefovir dipivoxil) and has received treatment continuously for a minimum of 5 months prior to screening. Other inclusion criteria may apply. Patient is pregnant or breastfeeding Patient is coinfected with hepatitis C, hepatitis D or HIV Patient previously received nucleoside(tide) therapy other than adefovir Patient previously received an interferonbased treatment or an investigational agent for hepatitis B in the preceding 12 months Other exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>